nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "ADHD"

 

Prevalence and Risk Factors Associated With Attention-Deficit/Hyperactivity Disorder Among US Black Individuals
September 24, 2020   

The worldwide prevalence of attention deficit/hyperactivity disorder (ADHD) is estimated to be 5.6%-7.2%. Prevalence rates of ADHD among Black individuals are reported to be lower than the rates of the general population. However, there is a paucity of primary studies with appropriate methodological design...
 Continue reading (Members only)
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
June 29, 2020   

The US Food and Drug Administration has recently approved use of a game-based digital device for the treatment of ADHD in youths aged 8-12 years...
 Continue reading
Positive Results for Brainsway’s Feasability Study of Deep Transcranial Magnetic Stimulation in the Treatment of Adults with ADHD
March 10, 2020   

The results from their randomized controlled double-blind clinical trial assessing the efficacy and safety of the company’s proprietary H6-coil deep transcranial magnetic stimulation (dTMS) System for the treatment of adults with attention deficit hyperactivity disorder (ADHD)...
 Continue reading
Acetaminophen and the Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood
February 21, 2020   

Studies have shown an association between self-reported maternal acetaminophen use during pregnancy and risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in offspring; however...
 Continue reading
FDA Allows Marketing of First Device to Treat ADHD
April 26, 2019   

The US Food and Drug Administration (FDA) recently permitted marketing for the first medical device to treat attention deficit hyperactivity disorder (ADHD). The device, called the Monarch external Trigeminal Nerve Stimulation System (eTNS) is indicated by...
 Continue reading
Risk of New-Onset Psychosis in ADHD is Higher with Amphetamine Than Methylphenidate
April 5, 2019   

Prescriptions for stimulants such as methylphenidate and amphetamine for the treatment of attention deficit -hyperactivity disorder (ADHD) have been on the rise. The Food and Drug Administration (FDA) mandated changes to drug labels for stimulants in 2007, on the basis of findings of...
 Continue reading
Saffron for Pediatric ADHD?
March 28, 2019   

Attention deficit-hyperactivity disorder (ADHD) is a common mental health issue among children and adolescents, affecting ~7% of school-age children. Existing treatments include stimulant medications (e.g., methylphenidate) and non-stimulants (e.g., atomoxetine), which work on dopaminergic and noradrenergic systems. These treatments are effective for some, but not all...
 Continue reading
Increased Risk of Basal Ganglia Disorders in Patients with a History of ADHD?
October 1, 2018   

A recent meta-analysis examined whether attention deficit hyperactivity disorder (ADHD), or treatments for the disorder alter the risk of diseases associated with the basal ganglia and cerebellum, including Parkinson’s disease...
 Continue reading
US Trends in Pediatric ADHD Diagnosis
September 17, 2018   

In this large epidemiological survey involving data from 186,457 children and adolescents (age 4-17 years) in the United States, the authors found that the prevalence of attention deficit-hyperactivity disorder has...
 Continue reading
1234
Top of Page